SyntheX is a biotechnology and pharmaceutical company that was founded by Charly Chahwan and Maria Soloveychik in 2016, and is headquartered in San Francisco, California. SyntheX uses a proprietary drug design approach and in-vivo screening platform, ToRPPIDO, to identify compounds that disrupt protein-protein interactions (PPIs). Their lead stabilized peptide inhibitor drugs, STX101 and STX105, block PPIs within the BRCA2 pathway, mimicking a BRCA2 mutation.
The SyntheX drug development technology can be used for creating drug products for use in oncology, membrane proteins, orphan diseases, antibiotic development, neuroinflammation, and immunology.
Synthex has 3 types of compounds in development: STX100's, STX200s, and STX300's. The STX100 includes compounds for HR-driven liver cancer, HR -driven pancreatic cancer, non-small cell lung cancer, and glioblastoma multiforme. The STX200 compounds are being made to treat KRAS-driven cancers, and the STX300 compounds are being made for an undislcosed target.